Is Dihexa Safe? Safety Profile 2026 — PeptidePrices

Q: Is Dihexa safe?

Dihexa has a safety rating of 4/10 in our methodology — caution. Acts via c-Met activation — a tumor-growth pathway — giving a real oncogenicity concern; no long-term or human safety data; no human trials. Generally avoided with any cancer history.

Q: Is Dihexa FDA approved?

FDA status: Not FDA-approved. PeptidePrices does not sell or recommend any compound for human use; this information is for research-context only.

Q: Where can I find verified Dihexa?

PeptidePrices tracks live prices and COA verification status across 30+ vendors. See our cheapest Dihexa listings for prices ranked by COA tier and $/mg.

Safety Profile

Dihexa

Updated today

Cognitive Peptide

4/10Caution

How we score compound safety →

Primary use: Cognitive / synaptogenesis research

Regulatory Status

Not FDA-approved

Safety Summary

Acts via c-Met activation — a tumor-growth pathway — giving a real oncogenicity concern
no long-term or human safety data
no human trials. Generally avoided with any cancer history.

Dihexa's 4/10 rating is in our caution tier. Either documented side-effect patterns are concerning, the human safety dataset is too thin to make confident statements, or the compound is under active regulatory scrutiny. We recommend reviewing the full notes above and consulting a licensed physician before any research use. Researchers often consider Semax and Selank as alternatives in the same category — see the related-compounds section below for safety comparisons.

Molecular Profile

TypeAngiotensin IV-derived HGF/MET potentiator

Molecular Weight535.72 g/mol

Amino Acids2 (modified dipeptide)

CAS Number1401708-83-5

Storage

Lyophilized−20°C, long-term stable

Reconstituted2–8°C, within 30 days

Protect from light
Avoid repeated freeze-thaw

Related Compounds

Methodology

How we rate peptide safety

Every compound in our index gets a 1–10 safety score based on four weighted factors. The score reflects known research-use risk — not medical advice.

40% — Clinical evidence. Volume of peer-reviewed trials, sample sizes, duration, and consistency of outcomes. FDA-approved compounds anchor the top end (8–10); preclinical-only compounds cap at 6.
30% — Adverse-event profile. Severity and frequency of reported side effects, including GI events, cardiovascular signals, hypoglycemia, and long-term organ effects.
20% — Regulatory status. FDA approval, EMA approval, or status in active clinical trials. Compounds under safety warnings are penalized.
10% — Community-reported outcomes. Reddit, forum, and published case-report signal beyond formal trials. Used as a late-stage tiebreaker, not a leading factor.

9–10Well-studied, FDA-approvedLarge-trial evidence, established long-term safety. Examples: semaglutide, tesamorelin at approved doses.

7–8Mostly safe, some caveatsPhase 2/3 evidence or long community track record with known manageable side effects. Routine monitoring recommended.

5–6Mixed dataLimited clinical trials, mostly community/preclinical data. Real but uncertain risk profile.

3–4Caution advisedKnown side-effect patterns, thin safety data, or compounds under active regulatory scrutiny.

1–2Significant risk signalsDocumented serious adverse events (cardiovascular, hepatotoxicity, contamination) or withdrawn regulatory status.

Related compounds

Other compounds researchers compare with Dihexa

Full Dihexa profile Cheapest Dihexa deals

Safety ratings are derived from published clinical data, FDA approval status, and community-reported outcomes. They are not medical advice. Always consult a healthcare professional before using any research compound.